Chinese patent negotiations
U.S. Trade Representative's office is considering retaliatory tariffs on a number of Chinese products due to failure to reach agreement on patent and intellectual property protections, USTR announces Nov. 26. Among the issues cited are "deficiencies in China's patent law, in particular, the failure to provide product patent protection for chemicals, including pharmaceuticals." The list of goods on which tariffs might be imposed includes vitamins and antibiotics. USTR will continue negotiations and accept public comment until Jan. 2, and then decide whether to impose the tariffs. USTR targeted China for priority investigations under the "Special 301" section of trade statutes on May 26, 1991. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth